Delving into the Latest Updates on Ipafricept with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

Ipafricept (USAN/INN)

+ [2]

Target

Wnt

Mechanism

Wnt ligand inhibitors

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication-

Inactive Indication

Hepatocellular CarcinomaOvarian CancerPancreatic Cancer+ [2]

Originator Organization

Mereo BioPharma 5, Inc.

Active Organization-

Inactive Organization

Mereo BioPharma 5, Inc.

Bayer AG

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 9645812

Source: *****

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with sorafenib. OMP-54F28 will be administered IV on Day 1 of each 21-day cycle. The planned dose levels of OMP-54F28 are 5 and 10 mg/kg. Depending on safety in this study, additional lower or intermediate dose levels may be evaluated.

Start Date01 Jan 2014

Sponsor / Collaborator

Mereo BioPharma 5, Inc.

NCT02092363 / CompletedPhase 1

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with paclitaxel and carboplatin. OMP-54F28 will be administered IV on Days 1 of each 21-day cycle. Paclitaxel (175 mg/m2) and carboplatin (AUC = 5 mg/mL • min) will be administered IV on Day 1 of each cycle. A total of 6 cycles of paclitaxel and carboplatin will be given. Additional cycles may be given as per institutional standard of care after discussion with the Medical Monitor. Treatment with OMP-54F28 will continue after completion of treatment with paclitaxel and carboplatin. The planned dose levels of OMP-54F28 are 5 and 10 mg/kg.

Start Date01 Jan 2014

Sponsor / Collaborator

Mereo BioPharma 5, Inc.

NCT02050178 / CompletedPhase 1

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with nab-paclitaxel and gemcitabine. OMP-54F28 will be administered IV on Days 1 and 15 of each 28-day cycle. Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) will be administered IV on Days 1, 8, and 15 of each cycle. The planned dose levels of OMP-54F28 are 3.5 mg/kg and 7.0 mg/kg.

Start Date01 Nov 2013

Sponsor / Collaborator

Mereo BioPharma 5, Inc.

100 Clinical Results associated with Ipafricept

Login to view more data

100 Translational Medicine associated with Ipafricept

Login to view more data

100 Patents (Medical) associated with Ipafricept

Login to view more data

8

Literatures (Medical) associated with Ipafricept

15 Oct 2020·Clinical Cancer ResearchQ1 · MEDICINE

Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer

Q1 · MEDICINE

Article

Author: Kapoun, Ann M. ; Brachmann, Rainer K. ; O'Neil, Bert ; Stagg, Robert J. ; Denlinger, Crystal S. ; Dotan, Efrat ; Lenz, Heinz-Josef ; Shahda, Safi ; Uttamsingh, Shailaja ; Astsaturov, Igor ; Cardin, Dana B. ; Cohen, Steven J. ; Weekes, Colin ; Messersmith, Wells

AbstractPurpose:The recombinant fusion protein ipafricept blocks Wnt signaling, and in combination with gemcitabine and nab-paclitaxel caused tumor regression in xenografts. This phase Ib study evaluated the combination of ipafricept with nab-paclitaxel + gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma (mPDAC).Patients and Methods:Dose escalation started with standard dose nab-paclitaxel + gemcitabine and ipafricept (3.5 mg/kg days 1, 15). Because of fragility fractures seen with different anti-Wnt agents, following cohorts had ≥6 patients treated with ipafricept 3 to 5 mg/kg on day 1, and included bone marker monitoring and prophylactic bisphosphonates as indicated. On the basis of preclinical data, sequential dosing was evaluated in cohort 4 (ipafricept day 1 followed nab-paclitaxel + gemcitabine day 3). Objectives included safety, MTD, recommended phase II dose, pharmacokinetics, immunogenicity, pharmacodynamics, and efficacy.Results:A total of 26 patients were enrolled, five in cohort 1 and seven each in cohorts 2–4. ipafricept-related adverse events (AEs) of any grade included fatigue, nausea, vomiting, anorexia, and pyrexia. ipafricept-related AEs grade ≥3 included two events of aspartate aminotransferase elevation, and one each of nausea, rash, vomiting, and leucopenia. No dose-limiting toxicities or fragility fractures were observed. Nine patients (34.6%) had partial response, 12 (46.2%) stable disease as best response, with clinical benefit rate of 81%. Median progression-free survival was 5.9 m [95% confidence interval (CI), 3.4–18.4], median overall survival was 9.7 m (95% CI, 7.0–14). The study was terminated by the sponsor due to bone-related toxicity within this therapeutic program and concerns for commercial viability. One patient remains on therapy under compassionate use.Conclusions:Ipafricept can be administered with nab-paclitaxel + gemcitabine with reasonable tolerance. Wnt pathway remains a therapeutic target of interest in mPDAC.

16 Mar 2020·Oncology Research Featuring Preclinical and Clinical Cancer TherapeuticsQ2 · MEDICINE

Frizzled Receptors in Tumors, Focusing on Signaling, Roles, Modulation Mechanisms, and Targeted Therapies

Q2 · MEDICINE

Review

Author: Wang, Wei ; Zhao, Chenghai ; Sun, Yu

Wnt molecules play crucial roles in development and adult homeostasis through their receptors Frizzled proteins (Fzds). Fzds mediate canonical -catenin pathway and various noncanonical -catenin-independent pathways. Aberrant Fzd signaling is involved in many diseases including cancer. Wnt/-catenin is a well-established oncogenic pathway involved in almost every aspect of tumor development. However, Fzd-mediated noncanonical Wnt pathways function as both tumor promoters and tumor suppressors depending on cellular context. Fzd-targeted therapies have proven to be effective on cultured tumor cells, tumor cell xenografts, mouse tumor models, and patient-derived xenografts (PDX). Moreover, Fzd-targeted therapies synergize with chemotherapy in preclinical models. However, the occurrence of fragility fractures in patients treated with Fzd-targeted agents such as OMP-54F28 and OMP-18R5 limits the development of this combination. Along with new insights on signaling, roles, and modulation mechanisms of Fzds in human tumors, more Fzd-related therapeutic targets will be developed.

01 Aug 2019·Gynecologic OncologyQ2 · MEDICINE

A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer

Q2 · MEDICINE

Article

Author: Burger, Robert A ; Morgan, Mark A ; Farooki, Azeez ; Moore, Kathleen N ; McMeekin, D Scott ; Gunderson, Camille C ; Brachmann, Rainer Karl ; Stagg, Robert ; Mantia-Smaldone, Gina ; Kapoun, Ann M ; Sabbatini, Paul ; O'Cearbhaill, Roisin E

OBJECTIVESThe WNT pathway is an important oncologic driver of epithelial ovarian cancer (EOC). The first-in-class recombinant fusion protein ipafricept (IPA) blocks Wnt signaling through binding of Wnt ligands. This phase Ib trial was designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RPh2) for IPA in combination with taxane and platinum therapy (C/P).METHODSDose escalation started with a standard 3 + 3 design for IPA/C/P with q3w intravenous IPA on Day 1, in cycles 1 to 6 with C (AUC = 5 mg/ml·min) and P (175 mg/m²). For enhanced bone safety the trial was revised to 6-patient cohorts with a q3w regimen of IPA on Day 1 and C/P on Day 3 (IPA → C/P).RESULTS37 patients have been treated; 30 of whom were treated following protocol revision to q3w IPA(D1) → C/P(D3) (2 & 4 mg/kg). IPA-related TEAEs that occurred in ≥15% included: fatigue (40%); nausea (35%); diarrhea and decreased appetite (22%) each; dysgeusia (19%); and vomiting (16.2%). 22% reported ≥1 IPA related TEAE Grade ≥3 the most common of which was neutropenia at 16%. There were no DLTs; the MTD was not reached. The maximum administered dose based on bone safety was 6 mg/kg. The overall response rate (ORR) was 75.7%. Median PFS was 10.3 months (95% CI 8.5-14.2) and OS 33 months (95% CI 23.4-NR).CONCLUSIONSIPA is well tolerated in combination with sequential C/P. ORR, PFS and OS are comparable to historical data but bone toxicity at efficacy doses of this particular Wnt inhibitor limit further development in EOC.

100 Deals associated with Ipafricept

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11758	-	-	DB15045

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platinum-Sensitive Ovarian Carcinoma	Phase 1	US	Mereo BioPharma 5, Inc.	01 Jan 2014
Solid tumor	Phase 1	US	Bayer AG	01 Jun 2012
Hepatocellular Carcinoma	Phase 1	-	Bayer AG	-
Hepatocellular Carcinoma	Phase 1	-	Bayer AG	-
Ovarian Cancer	Phase 1	-	Bayer AG	-
Pancreatic Cancer	Phase 1	-	Bayer AG	-
Pancreatic Cancer	Phase 1	-	Bayer AG	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02050178 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Pancreatic Cancer First line	26	Gemcitabine+nab-paclitaxel+Ipafricept	(abisedlqhi) = qbiolgnifg yfibbkaygo (yfdikaumzv, 3.4 - 18.4) View more	Negative	15 Oct 2020
NCT02092363 (Pubmed \| Obstet Gynecol Surv) Manual	Phase 1	Platinum-Sensitive Ovarian Carcinoma	37	paclitaxel+carboplatin+ipafricept	(grhubkhlcr) = axbxjcvjtt hoydkhjida (erccuchlgz ) View more	Positive	01 Aug 2019
NCT02050178 (ASCO_GI2019)	Phase 1	Pancreatic Cancer	26	Ipafricept + Nab-P/G	(narcrtofhc) = included 2 events of AST elevation, and 1 each of nausea, maculopapular rash, vomiting and WBC decrease nmxsbtscrp (svyipwzwbo ) View more	Positive	29 Jan 2019
NCT01608867 (Pubmed) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	26	Ipafricept	(gzaegduusc) = 15 mg/kg；Q3W drtobhbilg (zelcygkquf ) View more	Positive	15 Dec 2017
Phase 1b clinical studies (AACR2014)	Phase 1	Hepatocellular Carcinoma \| Ovarian Cancer	-	OMP-54F28	gjmwgsedcu(jeqegmfaod) = induction nkwqjxnwsu (hummwdtuaw ) View more	Positive	01 Oct 2014
Phase 1b clinical studies (AACR2014)	Phase 1	Hepatocellular Carcinoma \| Ovarian Cancer	-	OMP-54F28 + Sorafenib		Positive	01 Oct 2014
NCT01608867 (ASCO2014)	Phase 1	HR-positive/HER2-low Solid Tumors	25	OMP-54F28	(degyxyzhor) = mqrmwchujr kjfdhjxjym (zvwngtahwl ) View more	-	20 May 2014